Jan 25 (Reuters) - European Medicines Agency:
* EMA PUBLISHED CLINICAL DATA SUPPORTING EXTENSION OF INDICATION FOR SPIKEVAX TO INCLUDE USE IN ADOLESCENTS AGED 12 TO 17. Further company coverage:
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
121.4 USD | -1.13% |
|
+2.63% | +22.10% |
Jul. 12 | China approves CSPC Pharma's RSV vaccine for clinical trials | RE |
Jul. 10 | Flagship Pioneering Raises $3.6B for 'New Wave' of Health, AI Innovation | MT |
Jan 25 (Reuters) - European Medicines Agency:
* EMA PUBLISHED CLINICAL DATA SUPPORTING EXTENSION OF INDICATION FOR SPIKEVAX TO INCLUDE USE IN ADOLESCENTS AGED 12 TO 17. Further company coverage:
1st Jan change | Capi. | |
---|---|---|
+22.10% | 46.55B | |
+46.45% | 41.84B | |
-3.12% | 40.84B | |
+36.10% | 32.95B | |
-6.30% | 28.27B | |
+18.71% | 27.78B | |
+46.15% | 14.26B | |
+44.52% | 13.69B | |
+0.19% | 12.18B | |
-8.55% | 11.14B |